We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+3.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.89B
AUM Growth
+$345M
Cap. Flow
-$69.9M
Cap. Flow %
-2.42%
Top 10 Hldgs %
30.33%
Holding
133
New
31
Increased
28
Reduced
22
Closed
15

Top Buys

Rank Stock Value
1
QTTB icon
Q32 Bio
QTTB
+$97.6M
2
CNC icon
Centene
CNC
+$61.3M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$51.5M
4
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
+$41.1M
5
CVS icon
CVS Health
CVS
+$39.5M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$52.4M
2
GKOS icon
Glaukos
GKOS
+$51.5M
3
PODD icon
Insulet
PODD
+$41.5M
4
MCK icon
McKesson
MCK
+$38.1M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$35.8M

Sector Composition

Rank Sector Weight
1 Healthcare 74.89%
2 Financials 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIEN
101
DELISTED
Sientra, Inc.
SIEN
$1.06M 0.04%
+11,000
New +$1.21M
KIDS icon
102
OrthoPediatrics
KIDS
$502M
$877K 0.03%
58,247
– –
AKTX
103
Akari Therapeutics
AKTX
$19.8M
– –
-312
Closed -$1.08M
APLS
104
DELISTED
Apellis Pharmaceuticals
APLS
– –
-513,000
Closed -$11.1M
MCK icon
105
CALL
McKesson
MCK
$98B
– –
-43,200
Closed -$6.74M
MDXG icon
106
MiMedx Group
MDXG
$635M
– –
-150,000
Closed -$1.89M
NCNA
107
NuCana
NCNA
$5.24M
– –
-17
Closed -$835K
PTGX icon
108
Protagonist Therapeutics
PTGX
$8.9B
– –
-225,000
Closed -$4.68M
XFOR icon
109
X4 Pharmaceuticals
XFOR
$348M
– –
-731
Closed -$1.68M
RVNC
110
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-1,000,000
Closed -$35.8M
DCPH
111
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-336,009
Closed -$7.62M
EIGR
112
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-10,000
Closed -$4.18M
ALNA
113
DELISTED
Allena Pharmaceuticals
ALNA
– –
-605,100
Closed -$6.09M
FPRX
114
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-450,728
Closed -$9.88M
PTLA
115
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-298,545
Closed -$13.1M
LOXO
116
DELISTED
Loxo Oncology, Inc
LOXO
– –
-169,000
Closed -$14.2M
EVHC
117
DELISTED
Envision Healthcare Holdings Inc
EVHC
– –
-676,000
Closed -$23.4M
1 2 3 4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2018 Portfolio in Review

As of Q1 2018, Deerfield Management held 133 positions worth $2.89B, up 14% from $2.54B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Deerfield Management's Q1 2018 filing shows 31 new, 28 increased, 22 reduced and 15 closed positions. Its largest new stake was Q32 Bio: 290,391 shares worth $97.7M. The largest sale was DexCom, an estimated $52.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Financials.

  • Deerfield Management's largest Q1 2018 buy was Q32 Bio: 290,391 shares worth $97.7M.
  • Deerfield Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q1 2018, an estimated $51.5M increase.
  • Deerfield Management's biggest Q1 2018 reduction was DexCom, cutting an estimated $52.4M.
  • Deerfield Management fully exited Revance Therapeutics, Inc. in Q1 2018, selling an estimated $35.8M.
  • Deerfield Management's ten largest holdings make up 30% of its $2.89B portfolio in Q1 2018.
  • Deerfield Management opened 31 new positions and closed 15 in Q1 2018.
  • Deerfield Management's portfolio value rose 14% quarter-over-quarter to $2.89B.

Based on Deerfield Management's 13F filing for Q1 2018, filed 15 May 2018.